Search PubMed⌕ Search

Biomedical subjects

M Kiriyama

Publications and source records attributed to M Kiriyama.

At least 91 records · Page 5Linked to original sources
PubMed1993

Surgical therapy for apical invasive lung cancer: different approaches according to tumor location.

Thirty-one patients with apical invasive lung cancer were reviewed. The tumor occupied the anterior portion of the lung apex in four, the middle portion in one, the posterior portion in 17, and the entire apex in nine. Nine patients were treated by irradiation alone. Twenty-two patients underwent en bloc resection of the apical chest wall and the lung. Seventeen patients were operated on by different approaches: anterior and hook, according to the location of the lesion. Nine patients were operated on by the anterior approach and eight by the hook approach. Another five patients were operated on by the conventional postero-lateral approach. Lesions of the sternum and subclavian vessels and ipsilateral supraclavicular lymph nodes were resected by the anterior approach. Lesions of the vertebrae, brachial plexus, subclavian vessels and ipsilateral supraclavicular lymph nodes could be resected by the hook approach. The anterior approach was suited for lesions in the anterior portion or middle portion and the hook approach for lesions in the middle or posterior.

Adult↗
PubMed1993

[Intraarterial infusion chemotherapy for recurrent or unresectable gastric cancer].

Sixteen patients with recurrent or unresectable gastric cancer were treated by intraarterial infusion chemotherapy. The tip of the catheter was located at the 9-10th Th level in the aorta of 14 patients and in the common hepatic artery of two. The drug combination was methotrexate + 5-fluorouracil (5-FU), cisplatin, mitomycin C (MMC) + etoposide and MMC + 5-FU. Side effects such as bone marrow suppression, diarrhea and appetite loss were seen in 63% (10/16). The response rate was 36% (4/11) in those who were evaluated, and another three showed relief from symptoms. Median survival time was 11 months, and the one year survival rate was 41%, while two patients showing PR have been alive for more than one year.

Adult↗
PubMed1993

Hepatic resection guided by needles inserted under ultrasonographic guidance.

BACKGROUND: Operative ultrasonography for orienting the direction of transection of the liver is often useful in obtaining an adequate disease-free surgical margin. We have devised a new technique for hepatectomy guided by needles inserted under ultrasonographic guidance. METHODS: One hundred two hepatectomies were performed between January 1987 and September 1991, and the hepatectomy with this technique was begun in January 1989. RESULTS: In 10 of 29 limited hepatectomies performed in the first phase of the period in which this technique was not available, disease-free surgical margin of less than 1 cm was left because of inadequately directed division. Disease-free surgical margin of more than 1 cm was left in 18 of 23 limited hepatectomies in the second phase of the period in which this technique was available. In the other five operations where disease-free surgical margin of less than 1 cm was left, carcinomas were located too close to the major hepatic vessels. The average blood loss during the limited hepatectomies was reduced by this technique. Two-year and 3-year survival of patients undergoing hepatectomy for hepatocellular carcinoma were more favorable in the second phase than in the first phase. CONCLUSIONS: Although the difference between the two groups was not significant, this technique is useful in performing adequate transection of the liver.

Adenoma, Bile Duct↗
PubMed1993

[Tumor-node-metastasis classification for thymic epitherial tumors].

We applied the tentative TNM classification of thymoma to 24 cases of IV b thymoma, 59 cases of thymic carcinoma, and 26 cases of thymic carcinoma (109 cases in total). This classification was useful in these cases because cases could be divided into different grades (e.g. N 0, N 1, N 2, N 3) of the factor N (lymph node metastasis) without any shift to particular grades. Based on this finding, we hereby propose a TNM classification of thymic epitherial tumors which was prepared by slightly modifying the tentative TNM classification of thymoma.

Carcinoid Tumor↗
PubMed1992

Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival.

Immunohistochemistry using the avidin-biotin-peroxidase complex method was performed to study the production of alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC) tissue specimens which were obtained surgically. The relationship between staining for AFP and serum AFP levels or pathological findings was examined. The prognosis of the patients with HCC who underwent curative hepatic resections was studied with respect to the staining for AFP in their tumors. The mean serum AFP level in patients with positive AFP staining was significantly higher than in those with negative AFP staining. No significant relationship was found between AFP positivity and tumor size, tumor encapsulation, degree of vascular invasion, or the histological differentiation grade of the tumor. The patients with AFP-positive carcinomas had a poorer prognosis than did those with AFP-negative carcinomas (5-year survival rate of AFP-positive and negative groups were 26.7% and 56.5%, respectively.

Carcinoma, Hepatocellular↗
PubMed1992

[Prevention of postoperative recurrence of hepatocellular carcinoma by adjuvant locoregional chemotherapy].

Postoperative adjuvant locoregional chemotherapy was performed on patients who underwent hepatic resection for hepatocellular carcinoma with permeation of tumor into portal vein and/or into hepatic vein and/or intrahepatic metastasis to prevent recurrence. Twenty patients received intra-hepato-arterial infusion of chemotherapeutic drugs or Lipiodol, or transcatheter arterial embolization as adjuvant therapy, and 25 patients did not receive the therapy. There was no significant difference in the recurrence rate between the two groups, and disease-free-survival would not be improved significantly by adjuvant therapy. But the disease-free-survival was improved in patients who underwent relative noncurative hepatectomies. Median duration from the hepatic resection to the recurrence was prolonged by adjuvant therapy, but no significant difference was noted between the two groups. Serious hepatic injury was a side effect of adjuvant therapy in one patient. Therefore great care was necessary when performing the therapy. Further study on choice of the drugs and methods was considered necessary to obtain more effective therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

[Surgical treatment of advanced hepatocellular carcinoma].

One hundred and thirty-two patients with hepatocellular carcinoma in stages III and IV were studied. Seventy-six patients who underwent hepatectomy were divided into three groups: relative curative resection (RC: n = 30), relative noncurative resection (RNC: n = 30) and absolute noncurative resection (ANC: n = 16). Fifty-six patients were treated by non surgical procedures such as hepatic arterial infusion, transcatheter arterial embolization, ethanol injection and hyperthermia. The cumulative survival rate of hepatectomy patients was significantly better than that of non-surgically treated patients. The most significant prognostic factor was the presence of the portal venous invasion. In the patients without tumor thrombi or with tumor thrombi found microscopically, the cumulative survival rates of both RC and RNC were significantly better than those of ANC and non-surgically treated patients, but in the patients with tumor thrombi found grossly, there was no difference between hepatectomy patients and non-surgically treated patients. These results indicate that surgical treatment for advanced hepatocellular carcinoma improve the prognosis of the patients without tumor thrombi found grossly.

Aged↗
PubMed1992

[Evaluation of intraoperative intraperitoneal administration on anti-cancer drug for gastric cancer].

This study was undertaken in order to evaluate the effect of intraoperative intraperitoneal (IP) administration of cisplatin (CDDP) and/or mitomycin C (MMC) on patients who underwent an operation for gastric cancer, compared with an untreated group. There were no differences between the effect of CDDP and that of MMC. No differences were found between the survival rate of IP and untreated group in no liver and no peritoneal metastasis cases, nor in non-resection cases. However, the median survival time was longer at 377 days in IP group than at 213 days in the untreated group (p less than 0.1). The free CDDP levels in the serum after 50 mg IP injection remained effective for 15-30 min. On the other hand, the MMC levels in the serum after 20 mg IP proved in effective.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1990

[Spread of surgical indication for hepatoma with postoperative transcatheter arterial infusion].

UNLABELLED: We evaluated the reduction surgery and the postoperative TAI for unresectable hepato-cellular carcinoma (HCC). Eight patients underwent reduction surgery and postoperative TAI (group I). Twenty-five patients underwent combination therapy with TAI, TAE, EI, hyperthermia and irradiation, who had not undergone reduction surgery (group II). Nine patients underwent a relative noncurative operation (group III). We studied the prognosis of these three groups. RESULTS: The one-year survival rates were 85.7% in group I, 38.6% in group II and 55.5% in group III. The three-year survival rates were 42.9% in group I, 10.7% in group II and 55.5% in group III. There was a significant difference of prognosis between group I and group II (p less than 0.05, generalized Wilcoxon). These results suggest that reduction surgery and post operative TAI for unresectable HCC improve the prognosis.

Antineoplastic Agents↗
PubMed1988

[An intractable gastric cancer showing an extremely effective response to immunochemotherapy].

Reported herein is the case of a terminal patient with advanced gastric cancer who was shown an extremely effective response to immunochemotherapy. The patient, a 62-year-old female, was determined as having a gastric cancer, Borr. type 2, originating in the pyloric antrum. The tumor was found to be H3P3S2N2 (stage IV), and its histology revealed a mucus-producing papillary adeno-carcinoma, ss gamma, n(+), ly2, and V1. Thus the patient underwent a distal gastrectomy, and was given an operative administration of MMC, followed by postoperative immunochemotherapy with FT 207 and OK 432. Consequently, no ascites were noticed throughout the recuperative course, and repeated CT scannings of the hepatic metastatic lesions, revealed a remarkable regression. Two years after this operation, she resumed normal daily life. Further, her preoperatively elevated tumor markers have returned to normal.

Adenocarcinoma, Papillary↗
PubMed1986

[A case of retroperitoneal alveolar soft part sarcoma].

We present the first case of retroperitoneal alveolar soft part sarcoma (ASPS) to be reported in Japan. The patient was a 27-years-old woman. After the retroperitoneal (tumors were) removed, bilateral lung metastasis was found and removed. Shortly thereafter, a recurrent retroperitoneal tumor arose, but because removal of the tumor was impossible, injection of 100 mg of cisplatin and 100 mg of adriamycin into the feeding artery was performed, and radiotherapy was also undertaken. However, the treatments were not effective, and the patient is now being followed on an outpatient basis.

Adult↗
PubMed1986

[Distribution of 1-hexycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer].

The distribution of 1-hexylcarbamoyl-5-fluorouracil (HCFU), one of the "masked-type" derivatives of 5-fluorouracil (5-FU), was studied following oral administration in rats and human patients with colorectal cancer. In rats, the highest level of 5-FU from HCFU was shown in the stomach and kidney, followed by the large intestine. After oral administration of HCFU for seven days, the level of 5-FU in tumors from patients was higher than that in tumors from patients given single administration. The clinical response of HCFU administered orally was then evaluated in patients with colorectal cancer. Out of 25 evaluable patients the overall response rate including a CR and six PRs was 28.0%. Overall survival rates for patients were 75.0% in one year, 32.0% in two years, and 13.6% in three years. From these results, it was suggested that HCFU is a useful anticancer agent for colorectal cancer.

Adenocarcinoma↗